Approved Financial Results and Limited Review Report for the Quarter ended on 31.12.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.7 pts less than Nifty Microcap 250 and 7.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vasundhara Rasayans Ltd reported weak Q3 FY26 results with revenue from operations at Rs. 744.77 lakhs, down 15.6% from Rs. 882.16 lakhs in the year-ago quarter. Net profit after tax fell sharply to Rs. 72.05 lakhs from Rs. 145.28 lakhs YoY, a decline of about 50%, while EPS dropped to Rs. 2.21 from Rs. 4.57. For the nine months ended December 2025, revenue declined 9.2% to Rs. 2,382.99 lakhs and net profit fell 13.1% to Rs. 335.05 lakhs. Profitability margins compressed significantly as total expenses remained elevated relative to shrinking top-line. The statutory auditor Mamta Jain & Associates issued an unqualified limited review report with no qualifications or emphasis of matter.
Sharp YoY declines in both revenue (~16%) and net profit (~50%) signal operational headwinds and margin pressure. This is a negative development for shareholders and may weigh on the stock in the near term.